Titelbild

Scientific Advisory Board

 
Portrait

Percy A. Knolle, MD, Technical University Munich

Percy Knolle conducts research on the molecular and cellular mechanisms of organ-specific immune regulation. The main focus of this work is on liver immunology. His research contributes to understanding the immune competence of peripheral organs and lays the foundation for novel immunotherapeutic approaches to target chronic liver infection and cancer.

After studying medicine at the universities of Frankfurt, Paris, Birmingham, Geneva and Strasbourg, he did his doctoral studies at the German Cancer Research Center in Heidelberg. Having completed his training leading to German medical board certification in internal medicine/hepatology at the University Hospital of Mainz, he pursued a career in research at the Centre for Molecular Biology in Heidelberg. In 2002 he set up the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn. Since 2013, he has served as founding director of the Institute of Molecular Medicine (MOMENTUM) at the TUM School of Medicine.

 
Portrait

Percy A. Knolle, MD, Technical University Munich

Percy Knolle conducts research on the molecular and cellular mechanisms of organ-specific immune regulation. The main focus of this work is on liver immunology. His research contributes to understanding the immune competence of peripheral organs and lays the foundation for novel immunotherapeutic approaches to target chronic liver infection and cancer.

After studying medicine at the universities of Frankfurt, Paris, Birmingham, Geneva and Strasbourg, he did his doctoral studies at the German Cancer Research Center in Heidelberg. Having completed his training leading to German medical board certification in internal medicine/hepatology at the University Hospital of Mainz, he pursued a career in research at the Centre for Molecular Biology in Heidelberg. In 2002 he set up the Institute of Molecular Medicine and Experimental Immunology at the University of Bonn. Since 2013, he has served as founding director of the Institute of Molecular Medicine (MOMENTUM) at the TUM School of Medicine.

 
Portrait

Horst Weller, PhD, University Hamburg

Horst Weller is a leading nanotechnologist, who has made significant contributions to the understanding and widespread use of nanoparticles. He studied chemistry in Göttingen and for his post-doc went to the Hahn-Meitner Institute in Berlin, where nanoparticles had just emerged and were being investigated for catalytic application. At the University of Hamburg, he and his group developed nanotechnology into a truly interdisciplinary science with numerous applications in chemistry, material sciences and life sciences. In addition to his professorship at the University of Hamburg, he also is the Scientific Director of the Center for Applied Nanotechnology (CAN) in Hamburg.

 
Portrait

Horst Weller, PhD, University Hamburg

Horst Weller is a leading nanotechnologist, who has made significant contributions to the understanding and widespread use of nanoparticles. He studied chemistry in Göttingen and for his post-doc went to the Hahn-Meitner Institute in Berlin, where nanoparticles had just emerged and were being investigated for catalytic application. At the University of Hamburg, he and his group developed nanotechnology into a truly interdisciplinary science with numerous applications in chemistry, material sciences and life sciences. In addition to his professorship at the University of Hamburg, he also is the Scientific Director of the Center for Applied Nanotechnology (CAN) in Hamburg.

 
Portrait

Thomas Jung, MD, PhD, Inflazome Ltd.

Thomas Jung is a physician-scientist experienced in translational sciences, pre-clinical and clinical development of small molecules as well as biologics. He is currently Chief Medical Officer at Inflazome Ltd. He most recently served as Chief Development Officer at Auris Medical (Switzerland). Before that, he was Chief Medical Officer for Delenex Therapeutics (Switzerland). Prior to joining the biotech industry, Thomas was a member of Novartis’ R&D Group for 13 years. His most recent role there was Head of Translational Medicine EU. Thomas is a member of the Supervisory Board for AIMM Therapeutics (The Netherlands). He is a board certified Dermatologist and is an Associate Professor of Dermatology at the University of Göttingen, Germany.

 
Portrait

Thomas Jung, MD, PhD, Inflazome Ltd.

Thomas Jung is a physician-scientist experienced in translational sciences, pre-clinical and clinical development of small molecules as well as biologics. He is currently Chief Medical Officer at Inflazome Ltd. He most recently served as Chief Development Officer at Auris Medical (Switzerland). Before that, he was Chief Medical Officer for Delenex Therapeutics (Switzerland). Prior to joining the biotech industry, Thomas was a member of Novartis’ R&D Group for 13 years. His most recent role there was Head of Translational Medicine EU. Thomas is a member of the Supervisory Board for AIMM Therapeutics (The Netherlands). He is a board certified Dermatologist and is an Associate Professor of Dermatology at the University of Göttingen, Germany.

 
Portrait

Johannes Herkel, PhD, University Medical Centre Hamburg-Eppendorf (UKE)

Johannes Herkel is professor in the Department of Medicine I at the University Medical Centre Hamburg-Eppendorf (UKE). He is co-inventor of the Topas tolerogenic technology platform. His major scientific interests are the regulation of immune responses in the liver, the pathogenesis of autoimmune diseases and the identification of mechanisms and molecules that control the activity of the immune system. The ultimate goal of his research activities is the development of treatments for immune-mediated disorders.

 
Portrait

Johannes Herkel, PhD, University Medical Centre Hamburg-Eppendorf (UKE)

Johannes Herkel is professor in the Department of Medicine I at the University Medical Centre Hamburg-Eppendorf (UKE). He is co-inventor of the Topas tolerogenic technology platform. His major scientific interests are the regulation of immune responses in the liver, the pathogenesis of autoimmune diseases and the identification of mechanisms and molecules that control the activity of the immune system. The ultimate goal of his research activities is the development of treatments for immune-mediated disorders.

 
Portrait

Hans-Dieter Volk, MD, Institute of Medical Immunology Charité Berlin, BIH Center for Regenerative Therapies (BCRT)

Hans-Dieter Volk is Professor of Immunology and head of both the Institute of Medical Immunology, Charité Berlin and BIH Center for Regenerative Therapies (BCRT), as well as deputy spokesman of the Berlin-Brandenburg School for Regenerative Therapies (BSRT). In addition, he is scientific head of the division Immunology of the Labor Berlin Charité Vivantes GmbH, Berlin. His work is focused on the implementation of new concepts in diagnosis of and therapies for immunological diseases. Hans-Dieter is an expert in coordinating and conducting clinical trials by biomarker development, monitoring new cell therapies and performing proof-of concept and investigator-initiated trials (all phase I/II). In addition, he was/ is co-editor/editorial board member of several high-impact journals, including the American Journal of Transplantation and Transplantation, and board member of several scientific medicine societies, including the German Society Immunology and German Society of Sepsis.

 
Portrait

Hans-Dieter Volk, MD, Institute of Medical Immunology Charité Berlin, BIH Center for Regenerative Therapies (BCRT)

Hans-Dieter Volk is Professor of Immunology and head of both the Institute of Medical Immunology, Charité Berlin and BIH Center for Regenerative Therapies (BCRT), as well as deputy spokesman of the Berlin-Brandenburg School for Regenerative Therapies (BSRT). In addition, he is scientific head of the division Immunology of the Labor Berlin Charité Vivantes GmbH, Berlin. His work is focused on the implementation of new concepts in diagnosis of and therapies for immunological diseases. Hans-Dieter is an expert in coordinating and conducting clinical trials by biomarker development, monitoring new cell therapies and performing proof-of concept and investigator-initiated trials (all phase I/II). In addition, he was/ is co-editor/editorial board member of several high-impact journals, including the American Journal of Transplantation and Transplantation, and board member of several scientific medicine societies, including the German Society Immunology and German Society of Sepsis.